Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

141. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. Full Text available with Trip Pro

Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. Many people who inject drugs (PWID) are denied treatment for hepatitis C virus (HCV) infection, even if they are receiving opioid agonist therapy (OAT). Research suggests that HCV in PWID may be treated effectively, but optimal models of care for promoting adherence and sustained virologic response (SVR) have not been evaluated in the direct-acting antiviral (DAA

2019 Annals of Internal Medicine Controlled trial quality: predicted high

142. Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B. Full Text available with Trip Pro

Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B. Hepatitis B virus (HBV) infection, a liver disease caused by hepatitis B virus, may lead to serious complications such as cirrhosis and hepatocellular carcinoma. People with HBV infection may have co-infections including HIV and other hepatitis viruses (hepatitis C or D), and co-infection may increase the risk of all-cause mortality. Chronic HBV infection increases morbidity and psychological stress (...) and is an economic burden on people with chronic hepatitis B and their families. Radix Sophorae flavescentis, an herbal medicine, is administered most often in combination with other drugs or herbs. It is believed that it decreases discomfort and prevents replication of the virus in people with chronic hepatitis B. However, the benefits and harms of Radix Sophorae flavescentis for patient-centred outcomes are not known, and its wide usage has never been established with rigorous review methodology.To assess

2019 Cochrane

143. Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients. Full Text available with Trip Pro

Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients. Currently, there is no specific immunosuppressive protocol for hepatitis C (HCV)-positive renal transplants recipients. Thus, the aim of this study was to evaluate the conversion effect to everolimus (EVR) on HCV in adult kidney recipients.This is an exploratory single-center, prospective, randomized, open label controlled trial with renal allograft recipients with HCV

2019 Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia Controlled trial quality: uncertain

144. Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy Full Text available with Trip Pro

Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy To evaluate the safety and efficacy of IONIS-GCGRRx, a 2'-O-methoxyethyl antisense oligonucleotide targeting the glucagon receptor (GCGR), and the underlying mechanism of liver transaminase increases in patients with type 2 diabetes on stable metformin therapy.In three phase 2, randomized, double-blind (...) within the normal reference range at the 50-mg dose. There were no other significant safety observations and no symptomatic hypoglycemia or clinically relevant changes in blood pressure, LDL cholesterol, or other vital signs. At week 14, IONIS-GCGRRx 100 mg did not significantly affect mean hepatic glycogen content compared with placebo (15.1 vs. -20.2 mmol/L, respectively; P = 0.093) but significantly increased hepatic lipid content (4.2 vs. -2.7%, respectively; P = 0.005) in the presence

2019 EvidenceUpdates

145. Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or -3 Infections: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or -3 Infections: A Systematic Review and Meta-Analysis Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or -3 Infections: A Systematic Review and Meta-Analysis | Archives of Clinical Infectious Diseases | Full Text ARTICLE AUTHORS ARTICLE INFO Archives of Clinical Infectious Diseases Infectious Diseases and Tropical Medicine Research Center, SBUMS Articles (...) About Journal , , , , Mohammad Hossein Khosravi , , , , Heidar Sharafi , , , Mohammad Saeid Rezaee-Zavareh , , , , Bita Behnava , , , Seyed Moayed Alavian , , , 1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, Iran 2 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran 3 Meta-Analysis Study Group, Iran Hepatitis Network, Tehran, Iran 4 Middle East Liver Disease (MELD) Center, Tehran

2019 Archives of Clinical Infectious Diseases

146. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. (Abstract)

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Although direct-acting antivirals have been used extensively to treat patients with chronic hepatitis C virus (HCV) infection, their clinical effectiveness has not been well reported. We compared the incidence of death, hepatocellular carcinoma, and decompensated cirrhosis between patients treated with direct-acting antivirals and those untreated, in the French ANRS CO22 (...) Hepather cohort.We did a prospective study in adult patients with chronic HCV infection enrolled from 32 expert hepatology centres in France. We excluded patients with chronic hepatitis B, those with a history of decompensated cirrhosis, hepatocellular carcinoma, or liver transplantation, and patients who were treated with interferon-ribavirin with or without first-generation protease inhibitors. Co-primary study outcomes were incidence of all-cause mortality, hepatocellular carcinoma

2019 Lancet

147. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Full Text available with Trip Pro

Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. The revolution in hepatitis C virus (HCV) treatment through the development of direct-acting antivirals (DAAs) has generated international interest in the global elimination of the disease as a public health threat. In 2017, this led WHO to establish elimination targets for 2030. We evaluated the impact of public health interventions on the global HCV epidemic and investigated whether WHO's

2019 Lancet

148. Hepatitis B Virus Infection in Pregnant Women: Screening

Hepatitis B Virus Infection in Pregnant Women: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Pregnant women The USPSTF recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit A View the Clinical Summary in Population Pregnant Persons Recommendation Screen for hepatitis B virus (HBV) infection. Grade: A Risk Assessment In the United States, new cases of HBV (...) test for detecting maternal HBV infection is the serologic identification of hepatitis B surface antigen (HBsAg). Screening should be performed in each pregnancy, regardless of previous HBV vaccination or previous negative HBsAg test results Screening Intervals A test for HBsAg should be ordered at the first prenatal visit. Women with unknown HBsAg status or with new or continuing risk factors for HBV infection (eg, injection drug use or a sexually transmitted infection) should be screened

2019 U.S. Preventive Services Task Force

149. AASLD?IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

AASLD?IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection - Ghany - 2020 - Hepatology - Wiley Online Library

2019 American Association for the Study of Liver Diseases

150. Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes Full Text available with Trip Pro

Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes - GOV.UK GOV.UK uses cookies to make the site simpler. Search Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes Monitor glucose levels closely in patients with diabetes during direct-acting antiviral therapy for hepatitis C, particularly within the first (...) 3 months of treatment, and modify diabetes medication or doses when necessary. Patients with diabetes may experience symptomatic hypoglycaemia if diabetic treatment is continued at the same dose due to potential for an enhanced hypoglycaemic effect. Published 18 December 2018 From: Therapeutic area: , , Contents Advice for healthcare professionals: rapid reduction in hepatitis C viral load during direct-acting antiviral therapy for hepatitis C may lead to improvements in glucose metabolism

2019 MHRA Drug Safety Update

151. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance on HIV, hepatitis B and C testing in the EU/EEA SCIENTIFIC AD VICE www.ecdc.europa.eu Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approachECDC SCIENTIFIC ADVICE Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approach ii This guidance was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Andrew J Amato-Gauci and Lara Tavoschi with the support of Helena (...) Kingdom Masoud Dara, World Health Organization (WHO) Regional Office for Europe, Denmark Michael Ninburg, World Hepatitis Alliance, United Kingdom Mika Salminen, National Institute for Health and Welfare, Finland Mojca Maticic, University Medical Centre Ljubljana, Slovenia Nikos Dedes, EATG/Positive Voice, Greece Peter Vickerman, University of Bristol, United Kingdom Philippa Easterbrook, WHO, Switzerland Raj Patel, IUSTI/NHS England, United Kingdom Ruta Kaupe, DIA+LOGS, Latvia Slim Fourati, European

2019 European Centre for Disease Prevention and Control - Public Health Guidance

152. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA Suggested citation: European Centre for Disease Prevention and Control. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Stockholm, December 2018 Reproduction is authorised, provided the source is acknowledged. PDF Print ISBN 978-92-9498-291-9 ISBN 978-92-9498-292-6 DOI 10.2900/809892 DOI 10.2900/579896 Catalogue number TQ-06-18-361-EN-N (...) Catalogue number TQ-06-18-361-EN-C © European Centre for Disease Prevention and Control, Stockholm, 2018 Scope and purpose of guidance The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. Figure 1. The case for integrated

2019 European Centre for Disease Prevention and Control - Public Health Guidance

153. Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double-Blind, Randomized Trial. Full Text available with Trip Pro

Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double-Blind, Randomized Trial. Between 50% and 86% of patients with autoimmune hepatitis (AIH) relapse after immunosuppression withdrawal; long-term immunosuppression is associated with increased risk of neoplasias and infections. Chloroquine diphosphate (CQ) is an immunomodulatory drug that reduces the risk of flares in rheumatologic diseases. Our aims were to investigate the efficacy and safety of CQ

2019 Hepatology communications Controlled trial quality: predicted high

154. Hepatitis C: Who should I test for hepatitis C?

Hepatitis C: Who should I test for hepatitis C? Who to screen/test | Diagnosis | Hepatitis C | CKS | NICE Search CKS… Menu Who to screen/test Hepatitis C: Who should I test for hepatitis C? Last revised in April 2020 Who should I test for hepatitis C? Offer hepatitis screening to asymptomatic people who are at high risk of hepatitis C virus (HCV) infection. People who have ever injected drugs. People who received a blood transfusion before 1991 or blood products before 1986, when screening (...) of blood donors for hepatitis C infection, or heat treatment for inactivation of viruses were introduced. People born or brought up in a country with an intermediate or high prevalence (2% or greater) of chronic hepatitis C, including Africa, Asia, the Caribbean, Central and South America, Eastern and Southern Europe, the Middle East, and the Pacific islands. Babies born to mothers infected with hepatitis C. Prisoners, including young offenders. Looked-after children and young people, including those

2019 NICE Clinical Knowledge Summaries

155. Hepatitis C: How should I test for hepatitis C?

Hepatitis C: How should I test for hepatitis C? How to test | Diagnosis | Hepatitis C | CKS | NICE Search CKS… Menu How to test Hepatitis C: How should I test for hepatitis C? Last revised in April 2020 How should I test for hepatitis C? A lengthy pre-test discussion is not needed unless the person requests it. Ask about exposure to , and ask about when the last known risk activity took place (to help establish the 'window period' 3–6 months from the time of last possible exposure). Be aware (...) on measures to reduce the risk of hepatitis C virus (HCV) infection. If the test is positive, can reduce the risk of and ensure that infection is not transmitted to contacts. Discuss details of how the result will be given, and ask about available support if the result is positive. Check you have correct contact details and know how the person prefers to be contacted. Arrange an appointment for the result to be given, if possible. HCV infection is diagnosed with an antibody test (which indicates

2019 NICE Clinical Knowledge Summaries

156. Hepatitis C

Hepatitis C Hepatitis C | Topics A to Z | CKS | NICE Search CKS… Menu Hepatitis C Hepatitis C Last revised in April 2020 Hepatitis C is a slow, progressive disease of the liver caused by infection with the blood-borne hepatitis C virus (HCV). Diagnosis Management Background information Hepatitis C: Summary Hepatitis C infection is a slow, progressive disease of the liver caused by the hepatitis C virus (HCV). It is an important, underdiagnosed, and undertreated cause of morbidity and mortality (...) transfusion (pre 1990s), re-use or inadequate sterilization of medical equipment, needlestick injury, and exposure to infected blood by other means (for example sharing a razor with an infected person). Less common routes include sexual transmission and vertical transmission (from mother to baby). Complications of chronic hepatitis C infection include cirrhosis, liver failure, and hepatocellular carcinoma. Testing for hepatitis C should be offered or considered if there are: Risk factors for hepatitis C

2019 NICE Clinical Knowledge Summaries

157. Hepatitis C: Scenario: Active hepatitis C infection

Hepatitis C: Scenario: Active hepatitis C infection Scenario: Active hepatitis C infection | Management | Hepatitis C | CKS | NICE Search CKS… Menu Scenario: Active hepatitis C infection Hepatitis C: Scenario: Active hepatitis C infection Last revised in April 2020 Scenario: Active hepatitis C infection From age 16 years onwards. How should I manage a person with hepatitis C in primary care? People with hepatitis C virus (HCV) infection should be under the care of a hepatologist or specialist (...) gastroenterologist. If acute hepatitis C virus (HCV) infection is suspected (hepatitis C antibody positive with of acute hepatitis and/or a likely recent is identified): Arrange a same-day assessment or seek immediate specialist advice. If chronic HCV infection is suspected (hepatitis C antibody positive and ribonucleic acid positive with no clinical features of acute hepatitis): Arrange an urgent referral. Confirm the person's address and telephone number at the time of referral, and use the practice's address

2019 NICE Clinical Knowledge Summaries

158. Hepatitis B: When should I test for hepatitis B?

Hepatitis B: When should I test for hepatitis B? When to test for hepatitis B | Diagnosis | Hepatitis B | CKS | NICE Search CKS… Menu When to test for hepatitis B Hepatitis B: When should I test for hepatitis B? Last revised in November 2019 When should I test for hepatitis B? Consider hepatitis B in the following groups: People who are asymptomatic who are infection. In particular screen opportunistically those who: Are more likely to have been exposed to hepatitis B (such as immigrants from (...) areas with a high prevalence, injecting drug users, and sex workers). Have been sexually assaulted. Have sustained a needlestick injury. Are HIV-positive. People with clinical features that could be indicative of hepatitis B: For acute infection, these include: A prodromal illness that includes fever, arthralgia, or a rash (that may appear about 2 weeks before the onset of jaundice, then resolves in acute hepatitis B). Non-specific malaise, fatigue, fever, nausea, and poor appetite. Right upper

2019 NICE Clinical Knowledge Summaries

159. Hepatitis B: What issues should I consider before prescribing hepatitis B vaccine?

Hepatitis B: What issues should I consider before prescribing hepatitis B vaccine? Hepatitis B vaccine | Prescribing information | Hepatitis B | CKS | NICE Search CKS… Menu Hepatitis B vaccine Hepatitis B: What issues should I consider before prescribing hepatitis B vaccine? Last revised in November 2019 What issues should I consider before prescribing hepatitis B vaccine? What types of hepatitis B vaccine are available? There are several hepatitis B vaccines licensed for use in the UK, all (...) of which are inactivated: Engerix B ® . Fendrix ® . HBvaxPRO ® . Two combined hepatitis A and B vaccines, Twinrix ® and Ambirix ® , are also available. [ ; ] What is the immunization schedule for the hepatitis B vaccine? Different hepatitis B vaccines, doses, and primary dosing schedules are recommended depending on the person's age and whether they are receiving haemodialysis. For further information, consult the . For most adult and childhood risk groups, an accelerated schedule should be used

2019 NICE Clinical Knowledge Summaries

160. Hepatitis B virus-Associated Intrahepatic Cholangiocarcinoma Has Distinct Clinical, Pathological and Radiological Characteristics: A Systematic Review Full Text available with Trip Pro

Hepatitis B virus-Associated Intrahepatic Cholangiocarcinoma Has Distinct Clinical, Pathological and Radiological Characteristics: A Systematic Review Hepatitis B virus-Associated Intrahepatic Cholangiocarcinoma Has Distinct Clinical, Pathological and Radiological Characteristics: A Systematic Review Official journal of the International Association of Surgeons, Gastroenterologists and Oncologists Surgery, Gastroenterology and Oncology Vol. 24, Nr. 1, Feb 2019 Hepatitis B virus-Associated (...) Intrahepatic Cholangiocarcinoma Has Distinct Clinical, Pathological and Radiological Characteristics: A Systematic Review Harry Ho Man Ng, Nathanelle Khoo, Jyothirmayi Velaga, Joe Yeong, Jin Yeo Teo, Brian K.P Goh, Albert Su-Chong Low, Chung Yip Chan, Tony Kiat Hon Lim, Ser Yee Lee Systematic Review, Feb 2019 Article DOI: 10.21614/sgo-24-1-5 Intrahepatic cholangiocarcinoma (ICC) is a rare hepatic malignancy with a poor prognosis. It is known that Hepatitis B is both a risk factor and a prognosis factor

2019 Surgery, Gastroenterology and Oncology